Safety Assessment of Artemether/Lumefantrine/Tinidazole on the Kidneys of Healthy and Diseased Mice

Elias Adikwu* and Udeme Owunari Georgewill

1Department of Pharmacology and Toxicology, Faculty of Pharmacy, Niger Delta University, Bayelsa State, Nigeria.
2Department of Pharmacology, Faculty of Basic Clinical Sciences, University of Port Harcourt, Rivers State, Nigeria.

Authors' contributions

This work was carried out in collaboration between both authors. Authors EA and UOG designed the study, performed literature search and statistical analysis, wrote the protocol, and wrote the first draft of the manuscript. Both authors read and approved the final manuscript.

ABSTRACT

Artemether/lumefantrine/tinidazole- (A/L/T) can be use for the treatment of malaria; therefore its safety assessment is imperative. This study assessed its safety on the kidneys of healthy and diseased mice. Fifty four Swiss albino mice were used for this study. Mice were diseased with Plasmodium berghei (1 × 10⁷) and treated with T (28.6 mg/kg), A/L (2.3/13.7mg/kg) and A/L/T for 4 days. Healthy mice were treated with T (28.6 mg/kg), A/L (2.3/13.7mg/kg) and A/L/T for 28 days. At the termination of treatment, the mice were weighed, sacrificed and blood samples were collected and examined for kidney biochemical markers. Kidneys were weighed and evaluated for oxidative stress markers and histology. T, A/L and A/L/T had no significant (p>0.05) effects on all evaluated parameters in diseased mice when compared to control. Body weight was decreased whereas kidney weight was increased in healthy mice treated with T, (p<0.05), A/L (p<0.05) and A/L/T (p<0.01) when compared to control. Significantly elevated serum creatinine, urea, uric acid levels with significantly decreased albumin, and total protein levels occurred in healthy mice treated with T.
1. INTRODUCTION

The kidney is required for several important functions including the sustenance of homeostasis, detoxification, and excretion of toxic drugs and metabolites, thus it is venerable to toxicant induced damage [1]. A number of drugs including antimalarial drugs (quinine, and artemesunate) have been associated with nephrotoxicity [2]. The presentation of nephrotoxicity varies from an acute or chronic decreased glomerular filtration rate to glomerular and tubular damage [3]. Although renal impairment is often reversible if the offending drug is discontinued, the condition can be costly and may require multiple interventions, including hospitalization [4].

Artemether based combinations including artemether/lumefantrine(A/L),artesunate/amodiaquine, artesunate/mefloquine are the currently recommended antimalarial therapies [5]. Artemisinin derivatives are recommended worldwide for treatment of malaria because of their high potency, rapid onset of action, broad malaria stage specificity, and favorable safety profile [6]. A/L has shown efficacy against uncomplicated P. falciparum malaria and chloroquine resistant P. falciparum [7]. It accounted for 73 % of ACTs procured in 2013 [8]. However, A/L may have nephrotoxic effect. Reversible nephrotoxicity, diminished glomerular filtration rate and increased urinary excretion of electrolytes have been reported [9,10].

Tinidazole (5-nitroimidazole drug) (T), which has been proven to be relatively safe is widely used for the treatment of amoebiasis and giardiasis [11]. However, potential antimalarial activity of T has been reported by some scholars. Studies in a chick model parasitized with Plasmodium gallinaceum treated with T showed increased survival time [11]. It cures liver stage of relapsing strain of P. cynomolgi, in ‘Rhesus’ macaques (Macaca mulatta) and blood stage infection when co-administered with chloroquine [12]. Open label human study showed that T monotherapy followed by weekly doses cleared blood stage infection with no recurrences of P. vivax [13]. In previous studies, we showed promising antimalarial activity of T in combination with A/L characterized by decreased paracetamia, prolonged survival time and decreased anemia in a mouse model infected with P. berghei [14]. In-view of the potential of antimalarial drug combinations to cause nephrotoxicity, this study assessed the safety of artemether/lumefantrine/tinidazole (A/L/T) on the kidneys of healthy and diseased mice.

2. MATERIALS AND METHODS

2.1 Animals and Drugs

Fifty four adult Swiss albino mice (20-25g) of both sexes were supplied by the animal unit of the Faculty of Basic Clinical Sciences, University of Port Harcourt, Rivers State. The mice were grouped and kept under natural conditions with free access to diet and water. The mice were acclimated for 2 weeks prior to the study. Artemether/lumefantrine (A/L) (IPAC Laboratory, India) and Tinidazole (T) (Norvatis) were used. The doses of T (28.6 mg/kg), A/L (2.3/13.7mg/kg) and A/L/T used were based on previous antimalodial studies [14].

2.2 Parasite Inoculation of Mice and Treatment

CQ sensitive strain of P. berghei in donor mice was provided by the Nigerian Institute of Medical Research (NIMR), Yaba, Lagos, Nigeria. Thirty Swiss albino mice grouped into 5 (I-V) of n=6 were used. Groups II-V were parasitized i.p with P. berghei containing 1 × 10⁷ parasitized erythrocytes and allowed for 3 days. On day 4, the mice were treated as follows: Group 1: (Normal control) and group II (Parasitized control) were orally treated with normal saline (0.2mL). Groups III-V were treated daily with T.
(28.6 mg/kg), A/L (2.3/13.7 mg/kg) and A/L/T for 4 days, respectively.

2.3 Treatment of Healthy Mice

In the sub-acute toxicity study, twenty four mice were grouped into four of (n=6) and treated with drugs as follows: Group 1: (Control) was orally treated with normal saline (0.2 mL) for 28 days. Groups II-IV were orally treated with T (28.6 mg/kg), A/L (2.3/13.7 mg/kg) and A/L/T for 28 days, respectively.

2.4 Animal Sacrifice

After treatment, the mice were weighed; fasted over night and anesthetized (diethylether). Blood samples were obtained from the heart, centrifuged (1200 rpm for 20 minutes) and sera extracted and assessed for biochemical markers. Mice were dissected, kidneys collected and rinsed in saline. Rinsed kidneys were homogenized in buffered (pH 7.4), 0.1 M Tris-HCl solution and centrifuged (2000 rpm for 20 minutes). The homogenates were decanted and assessed for oxidative stress markers.

2.5 Assessments of Serum Biochemical Markers

Sera were estimated for uric acid, creatinine, urea, total protein, albumin, sodium, potassium and bicarbonate using test kits.

2.6 Oxidative Stress Marker Assay

Kidney glutathione (GSH) was assayed according to Sedlacek and Lindsay [15]. Catalase (CAT) was assayed as explained by Aebi, [16]. Glutathione peroxidase (GPx) was measured according to Rotruck et al. [17]. Superoxide dismutase (SOD) was estimated as reported by Sun and Zigman [18]. Malondialdehyde (MDA) was measured as described by Buege and Aust [19].

2.7 Histology of the Kidney

Dissected kidney tissues were cut and fixed in Bouin’s solution for 24 hr. Kidney tissues were dehydrated in alcohol-graded series processed and embedded in paraffin wax. Sections (3 µm each) were cut and stained with Haematoxylin and Eosin on slides. The slides were examined using a light microscope and relevant sections photographed.

2.8 Statistical Analysis

Data were presented as mean ± SEM and assessed by one-way analysis of variance (ANOVA) followed by Tukey’s multiple range test (Graph Pad Prism 5 Software, San Diego, CA USA). Differences are statistically significant at p < 0.05; p < 0.01 and p < 0.001.

3. RESULTS

3.1 Effects of Artemether/Lumefantrine/Tinidazole on Body and Kidney Weights and Serum Biochemical Markers of Parasitized Mice

Treatment with T, A/L and A/L/T for 4 days did not produce significant (p > 0.05) effects on body and kidney weights of parasitized mice when compared to normal control (Table 1). Normal (p > 0.05) serum electrolytes, creatinine, urea, uric acid, total protein and albumin levels were observed in parasitized mice treated with T, A/L and A/L/T for 4 days when compared to normal control (Table 2).

Table 1. Effects of artemether/lumefantrine/tinidazole on body and kidney weights of healthy and parasitized mice

| Treatment     | Final body weight (g)       | Absolute kidney weight (g) | Relative kidney weight (%) |
|---------------|-----------------------------|-----------------------------|----------------------------|
|               | Healthy mice | Parasitized mice | Healthy mice | Parasitized mice | Healthy mice | Parasitized mice |
| Control   | 28.73±2.43          | 27.25±3.77          | 0.17±0.03         | 0.16±0.01         | 0.59±0.02       | 0.59±0.06         |
| T           | 23.52±2.90          | 27.94±2.58          | 0.20±0.01         | 0.15±0.04         | 0.85±0.06       | 0.54±0.01         |
| A/L         | 24.01±2.57          | 29.61±3.32          | 0.21±0.05         | 0.17±0.06         | 0.87±0.08       | 0.57±0.09         |
| A/L/T       | 20.99±3.56          | 29.96±2.11          | 0.25±0.09         | 0.16±0.02         | 1.12±0.05       | 0.54±0.04         |

T: Tinidazole, A/L: Artemether/lumefantrine, A/L/T: Artemether/lumefantrine/tinidazole. Data as mean ± SEM, n=6, * p<0.05 in comparison to control (Healthy mice), ** p<0.01 in comparison to control (Healthy mice), SEM: Standard error of mean.
Table 2. Effect of artemether/lumefantrine/tinidazole on serum kidney biochemical markers of healthy and parasitized mice

| Treatment | Healthy mice | Parasitized mice | Urea (mg/dL) | Uric acid (mg/dL) | Urea (mg/dL) | Uric acid (mg/dL) |
|-----------|--------------|------------------|--------------|------------------|--------------|------------------|
| Control   | 0.50±0.03    | 7.27±0.04        | 1.37±0.13    | 0.56±0.09        | 7.41±0.07    | 1.42±0.24        |
| T         | 0.97±0.07*   | 10.91±0.99       | 2.89±0.09*   | 0.54±0.03        | 7.33±0.01    | 1.40±0.45        |
| A/L       | 1.36±0.03**  | 13.83±0.36*      | 4.05±0.06**  | 0.57±0.07        | 7.30±0.05    | 1.38±0.67        |
| A/L/T     | 2.67±0.08    | 20.14±2.71**     | 7.76±0.72**  | 0.53±0.01        | 7.40±0.08    | 1.35±0.44        |

T: Tinidazole, A/L: Artemether/lumefantrine, A/L/T: Artemether/lumefantrine/tinidazole, Data as mean ± SEM, n=6, *p<0.05, **p<0.01, ***p<0.001 when compared to control (Healthy mice), SEM: Standard error of mean

Table 3. Effect of artemether/lumefantrine/tinidazole serum electrolytes of healthy and parasitized mice

| Treatment | Healthy mice | Parasitized mice | K (mmol/L) | Na (mmol/L) | Cl (mmol/L) | HCO3 (mmol/L) | K (mmol/L) | Na (mmol/L) | Cl (mmol/L) | HCO3 (mmol/L) |
|-----------|--------------|------------------|------------|-------------|-------------|---------------|------------|-------------|-------------|---------------|
| Control   | 4.33±0.03    | 120.25±11.7      | 133.74±12.6| 12.14±1.71  | 4.12±0.6    | 110.16±10.6   | 127.30±9.22| 13.31±1.65  |             |               |
| T         | 4.30±0.90    | 117.02±10.5      | 130.42±10.7| 12.37±0.42  | 4.10±0.01   | 109.17±12.1   | 125.56±10.6| 13.65±1.14  |             |               |
| A/L       | 4.27±0.57    | 118.64±12.3      | 128.36±10.5| 12.74±1.63  | 4.09±0.19   | 107.34±10.9   | 123.45±11.8| 13.36±1.90  |             |               |
| A/L/T     | 4.25±0.56    | 114.91±10.1      | 126.23±11.9| 12.60±1.24  | 4.06±0.24   | 105.45±11.4   | 122.37±12.5| 13.73±1.40  |             |               |

T: Tinidazole, A/L: Artemether/lumefantrine, A/L/T: Artemether/lumefantrine/tinidazole, Data as Mean ± SEM, n=6, SEM: Standard error of mean
3.2 Effects of Artemether/Lumefantrine/Tinidazole on Body and Kidney Weights and Serum Biochemical Markers of Healthy Mice

Body weight was significantly decreased whereas kidney weight was significantly increased in healthy mice treated with T (p<0.05), A/L (p<0.05) and A/L/T (p<0.01) for 28 days when compared to control (Table 1). Serum creatinine, urea and uric acid levels were significantly increased whereas total protein and albumin levels were significantly decreased in healthy mice treated with T (p<0.05), A/L (p<0.01) and A/L/T (p<0.001) for 28 days when compared to control (Table 3). Serum electrolytes (Sodium, potassium, chloride, and bicarbonate) were normal (p>0.05) in healthy mice treated with T, A/L and A/L/T for 28 days when compared to control (Table 3).

3.3 Effects of Artemether/Lumefantrine/Tinidazole on Kidney Oxidative Stress Markers and Histology of Healthy Mice

Kidney antioxidants (SOD, GSH, CAT and GPx) were significantly decreased in healthy mice treated with T (p<0.05), A/L (p<0.01) and A/L/T (p<0.001) for 28 days when compared to control (Table 4). On the other hand, MDA levels were significantly increased in healthy mice treated with T (p<0.05), A/L (p<0.01) and A/L/T (p<0.001) for 28 days when compared to control (Table 4). Kidney of control mice showed normal histology (Fig. A). Kidney of healthy mice treated with A/L showed enlarged Bowman’s space and tubular necrosis (Fig. B). Kidney of healthy mice treated with T showed tubular necrosis (Fig. C). Kidney of healthy mice treated with A/L/T showed enlarged Bowman’s space and tubular necrosis (Fig. D).

### Table 4. Effect of artemether/lumefantrine/tinidazole on kidney oxidative stress markers of healthy mice

| Treatment | MDA nmol/mg protein | GSH µmol/mg protein | CAT U/mg protein | SOD U/mg protein | GPx U/mg protein |
|-----------|---------------------|---------------------|------------------|-----------------|-----------------|
| Control   | 0.12 ± 0.02         | 8.44 ± 0.73         | 25.64 ± 2.01     | 14.85 ± 2.51    | 15.34 ± 1.00    |
| T         | 0.25 ± 0.04         | 6.05 ± 0.87         | 20.80 ± 2.33     | 11.01 ± 2.33    | 11.61 ± 0.32    |
| A/L       | 0.46 ± 0.06         | 4.35 ± 0.45         | 15.36 ± 1.71     | 9.00 ± 0.41     | 8.14 ± 0.71     |
| A/L/T     | 0.70 ± 0.03         | 2.22 ± 0.27         | 10.82 ± 0.79     | 6.01 ± 2.70     | 5.40 ± 0.26     |

T: Tinidazole, A/L: Artemether/lumefantrine, A/L/T: Artemether/lumefantrine/tinidazole, MDA: Malondialdehyde, GSH: Glutathione, CAT: Catalase, SOD: Superoxide dismutase, GPx: Glutathione peroxidase, Data as Mean ± SEM, n=6, *p<0.05, **p<0.01, ***p<0.001 compared to control, SEM: Standard error of mean

4. DISCUSSION

Previous study has shown the antiplasmodial activity of A/L/T in a mouse model infected with *P. bergei* [14]. Thus study further assessed the safety of A/L/T on the kidneys of healthy and *P. bergei* infected mice. Perturbations in body and organ weights are used in experimental studies to ascertain the toxic effects of chemical substances [20]. In this study, body and kidney weights were normal in parasitized mice treated with A/L/T. However, body weight was decreased whereas kidney weight was increased in healthy mice treated with A/L/T. Biomarkers of renal function are used to estimate the severity and nature of kidney injury, and to decipher appropriate therapy. Biomarkers including serum creatinine, urea and uric acid, total protein and albumin can be used to assess the extent of kidney perturbation. Creatinine gives a clear picture of glomerular filtration rate whereas total protein can accurately detect early kidney perturbation as well as chronic kidney perturbation [21]. In this study, renal function markers were normal in parasitized mice treated with A/L/T whereas, sub-acute toxicity study in healthy mice showed impaired renal function markers caused by A/L/T. This was characterized by elevated serum creatinine, urea and uric acid levels with decreased serum total protein and albumin levels. Electrolytes are positively and negatively charged ions, which are found within cells and extracellular fluids, including intestinal fluid, blood, and plasma. Electrolytes play important functions in cellular function, intermediary metabolism, enzyme activities and electrical gradients [22]. Fluctuations in serum electrolytes can predict the functional status of the kidney [23]. The current study observed normal serum electrolytes in parasitized mice and healthy mice treated with A/L/T. Oxidative stress is a state in which oxidation exceeds the
antioxidant systems, which can cause hazardous damage to biomolecules. It can also alter physiologic adaptation phenomena and the regulation of intracellular signal transduction. Low levels of antioxidants have been experimentally used to assess oxidative stress [24]. Lipid peroxidation is a chain reaction by which unsaturated fatty acids (cell membrane components) are oxidized in various pathological conditions. Many markers of lipid peroxidation have been proposed, including lipid peroxides, malondialdehyde, and 4-hydroxynonenal [24]. In the current study, healthy mice treated with A/L/T showed decreased kidney antioxidants with increased kidney malondialdehyde levels. This observation connotes oxidative stress. The kidneys of A/L/T treated healthy mice were distorted as marked by tubular necrosis and enlarged Bowman's space. This observation correlates with changes in serum renal function markers and kidney oxidative stress markers observed in A/L/T treated rats. A/L has been shown to cause nephrotoxicity characterized by alterations in serum creatinine, urea, and uric acid levels [25] which is consistent with the observation in this study. Also, changes in kidney oxidative stress markers and histology in A/L treated mice have been previously reported [25]. Studies have shown that T is relatively safe [11], but this study observed signs of nephrotoxicity in
treated healthy mice characterized by altered kidney histology, and serum renal function indices. Treatment with T also produced alterations in kidney oxidative stress markers of healthy mice.

5. CONCLUSION

The use of A/L/T as an antimalarial drug may be safe on the kidney, but long term use may cause kidney damage considering the dose and route used for this study. Cautioned is advised with long term use.

CONSENT

It is not applicable.

ETHICAL APPROVAL

Animal Ethic committee approval has been taken to carry out this study.

ACKNOWLEDGEMENT

The authors appreciate animal handling performed by the Laboratory staff of Pharmacology, Faculty of Basic Clinical Sciences, University of Port Harcourt, Rivers State, Nigeria.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Ferguson MA, Vaidya VS, Bonventre JV. Biomarkers of nephrotoxic acute kidney injury. Toxicology. 2008;245:182–193.
2. Wiwanitkit V. Antimalarial drug and renal toxicity. J Nephropharmacol. 2016;5(1):11-12.
3. Kane-Gill SL, Goldstein SL. Drug-induced acute kidney injury: a focus on risk assessment for prevention. Crit Care Clin. 2015;31(4):675-84.
4. Gandhi TK, Burstin HR, Cook EF, et al. Drug complications in outpatients. J Gen Intern Med. 2000;15(3):149-154.
5. Ehrhardt S, Meyer CG. Artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria. Therapeutics and Clinical Risk Management. 2009;5:805–815.
6. White NH, Breman JG. Malaria. Harrison’s principles of internal medicine. 17th ed. New York: McGraw-Hill. 2008;1280-94.
7. Stover KR, King ST, Robinson J. Artemether-Lumefantrine: An Option for Malaria the Annals of Pharmacotherapy. 2012;46:567-577.
8. World Health Organization (WHO). World malaria report 2014. Geneva: WHO; 2014. Available:http://www.who.int/malaria/publications/ world_malaria_report_2014/report/en/
9. Li Q, Xie LH, Johnson TO, Si Y, Haeberle AS, Weina PJ. Toxicity evaluation of artesunate and artelinate in Plasmodium berghei-infected and uninfected rats. Trans R Soc Trop Med Hyg. 2007;101:104-12.
10. Campos SB, Rouch LH, Seguro AC. Effects of sodium artesunate, a new antimalarial drug, on renal function. Kidney Int. 2001;59:1044-51.
11. Macareo L, Lwin KM, Cheah PY, et al. Triangular test design to evaluate tinidazole in the prevention of Plasmodium vivax relapse. Malar J. 2013;12:173 1-6.
12. Deye G, Gettayacamin M, Pranee H, Imterbsin R, Sattabongkot J, Rothstein Y, et al. Use of Rhesus Plasmodium cynomolgi model to screen for anti-hypnozoite activity of pharmaceutical substances. Am J Trop Med Hyg. 2012;86:931-935.
13. Sarma P. Tinidazole: A new drug in the treatment of vivax malaria. Curr Ther Res. 1988;43:3.
14. Georgewill UD, Melford H, Adikwu E. Antiplasmodial activity of artemether-lumefantrine-tinidazole on Plasmodium berghei infected mice The Pharm and Chem Jour. 2021;8(1):107-113.
15. Sedlak J, Lindsay RH. Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman’s reagent. Anal Biochem. 1968;25:192-205.
16. Aebi H. Catalase in-vitro. Methods Enzymol. 1984;105:121-6.
17. Rotruck JT, Pope AL, Ganther HE, Swanson AB, Hafeman DG, Hoekstra WG. Selenium: Biochemical role as a component of glutathione peroxidase. Sci. 1973;179:588-90.
18. Sun M, Zigma S. An Improved spectrophotometer assay of superoxide dismutase based on epinephrine antioxidation. Anal Biochem. 1978;90:81-9.
19. Buege JA, Aust SD. Microsomal lipid peroxidation. Meth Enzymol. 1978;52:302-10.
20. Elias Adikwu. Alpha lipic acid attenuates cyclophosphamide-doxorubicin-induced hepatic perturbation in rats. Journal of Marine Medical Science. 2020;22:62-8.
21. Krstic D, Tomic N, Radosavljevic B, et al. Biochemical markers of renal function. Current Medicinal Chemistry. 2016;23(19):2018-2040.
22. Lobo DN. Fluid electrolytes and nutrition. Physiological and clinical aspects. Proc Nutr Soc. 2004;63(3):453-466.
23. Gowda S, Desai PB, Kulkarni SS, Hull SV, Math AK, Vernekar SN. Markers of renal function tests. N Am J Med Sci. 2010;2(4):170-173.
24. Yoshikawa T, Naito Y. What Is Oxidative Stress? JMAJ. 2002;45(7):271–276.
25. Abolaji AO, Eteng MU, Omonua O, Adenrele Y. Influence of coadministration of artemether and lumefantrine on selected plasma biochemical and erythrocyte oxidative stress indices in female Wistar rats. Human & Experimental Toxicology. 2013;32(2):206-215.

© 2021 Adikwu and Georgewill.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:
The peer review history for this paper can be accessed here:
http://www.sdiarticle4.com/review-history/67220